TiumBio’s CEO shares his experiences as the original developer of hemophilia therapy Afstyla, the reason the rare disease-specialized company is exploring opportunities in Australia, as well as its R&D plans.

Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.

Michael Parini talks to Scrip about how a new focus at the company can help it prove the value of its AAV-based gene therapy platform.

Orchard Therapeutics says it is confident in the success of its gene therapy for MLD, which has secured the highest possible benefit rating from the German authorities.